Compare SWVL & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWVL | HIND |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United Arab Emirates | United States |
| Employees | N/A | 2 |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 15.2M |
| IPO Year | 2021 | 2016 |
| Metric | SWVL | HIND |
|---|---|---|
| Price | $7.14 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.7M | 6.1K |
| Earning Date | 04-20-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.43 |
| 52 Week Low | $1.30 | $1.75 |
| 52 Week High | $7.35 | $9.56 |
| Indicator | SWVL | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 94.05 | 37.17 |
| Support Level | $1.41 | $1.99 |
| Resistance Level | N/A | $2.34 |
| Average True Range (ATR) | 0.86 | 0.08 |
| MACD | 0.55 | -0.02 |
| Stochastic Oscillator | 90.14 | 0.00 |
Swvl Holdings Corp is a technology-driven mobility company providing mass transit solutions. It currently has two offerings: business-to-consumer (B2C) and B2B (marketed as Swvl Business). The company's B2C business utilizes its platform to provide riders with a network of minibuses and other vehicles that operate on fixed and semi-fixed routes throughout and between different cities. Riders can book available seats on vehicles to commute within a city. The Swvl Business caters to corporate customers (as well as schools and municipalities), providing them with transportation solutions for their employees and students. This business also offers transportation management software to clients who operate their own fleet. Geographically, the company generates maximum revenue from Egypt.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.